# Pizarra — PT-pseudo_4bfd4ec864d8 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4bfd4ec864d8
Task: 1

Encounter: Urology - outpatient on 02 Mar 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.35 ng/mL²
  - PSA velocity: 1.56 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 31.6 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.833 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NSAIDs
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 32 mL. DRE nodus. csPCa 0.83.

Vitals: weight 82 kg, height 183 cm, BMI 24.5, BP 118/75 mmHg, HR 66 bpm. Smoking: Non-smoker.

Chief complaint: Current evaluation addresses sustained PSA elevation alongside a newly identified PI-RADS 5 lesion on recent imaging.

History: The patient, a 72-year-old retired plumber, entered urological monitoring after an initial PSA rise in early 2022. He identifies as a non-smoker and currently resides in a ground-floor apartment with his partner, having been widowed. Respiratory management involves tiotropium alongside PRN salbutamol for his COPD. Urinary symptom burden remains low (IPSS 6), characterized mainly by sporadic nocturia, with explicit denial of haematuria or pelvic discomfort. Recreational gardening continues, and he recently finished six physiotherapy visits addressing chronic lower back ache unrelated to prostate pathology. Daily activity features regular neighbourhood walks. Notably, he reports no unexplained weight reduction, skeletal pain, or systemic complaints.

Physical examination: DRE — texture: asymmetrically enlarged gland; mobility: fixed; asymmetry: firm, discrete nodule localized to the right peripheral zone. Abdominal and cardiovascular assessments remain entirely unremarkable. Blood pressure is stable, and cardiac rhythm registers at 66 bpm.

Patient info: retired plumber; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Gardening, no structured exercise; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Radiology — chest X-ray (routine); Audiology — hearing test; Physiotherapy — lower back, six sessions.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.87 +/- 0.07   (95% CI 0.72-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.07  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.57 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

No frozen image embeddings are on file for this patient, so the image-embedding head could not be run. This contributes NO evidence in either direction — do not read the absence of a score as reassurance.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI prose confirm the PI-RADS 5 lesion and compare it against earlier studies?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on the interpretation of the PI-RADS 5 finding and the context of the prior negative biopsy. The agenda focuses on retrieving the imaging details, PSA trajectory, prior management, and specific lab data to determine if the protocol criterion for re-biopsy is met. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, missing crucial context such as the specific PSA velocity (1.56 ng/mL/yr), the PI-RADS 5 score, and the prior negative biopsy status in relation to the current imaging finding.
WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.87), but the guideline track record suggests that the decision hinges on the specific PI-RADS score (5) and the context of the prior negative biopsy, which the prior did not explicitly weigh. The high aleatoric uncertainty (H=0.57) indicates the model struggles with the data distribution, potentially failing to capture the nuance where a PI-RADS 5 finding combined with a prior negative biopsy might shift the risk profile away from a mandatory biopsy.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI prose confirm the PI-RADS 5 lesion and compare it against earlier studies?
psa_trend - What is the serial PSA trend and velocity beyond the headline value?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
GUIDELINE ANCHOR
The guideline criterion mandates a repeat biopsy when the mpMRI shows a PI-RADS 4-5 lesion, and the track record shows 16 of 18 cases matched the reading urologist.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_4bfd4ec864d8", "radiology_report": "Subject: Prostate Multiparametric MRI\nReporting Centre: OLVG Amsterdam\nDate: 28 February 2025\nClinical context: PSA 11.0 ng/mL with a PI-RADS 5 designation.\n\nFINDINGS:\nProstate parenchyma occupies a total volume of 31.6 mL. T2-weighted sequences highlight a sharply demarcated, markedly hypointense focus measuring 12 x 9 x 11 mm within the right peripheral zone at the mid-gland level. This area exhibits restricted diffusion on DWI with corresponding low signal intensity on the ADC map. Dynamic contrast-enhanced sequences show early, focal enhancement compared to adjacent tissue. Extracapsular extension, seminal vesicle invasion, suspicious lymphadenopathy, and osseous abnormalities are absent.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-peripheral zone.\nProstate volume 31.6 mL; PSA density 0.35 ng/mL/mL.\ncsPCa predicted probability 0.833."}
get_psa_trend
{"case_id": "PT-pseudo_4bfd4ec864d8", "psa_trend": [{"date": "Mar 2022", "val": 4.2}, {"date": "Dec 2022", "val": 5.3}, {"date": "Sep 2023", "val": 6.8}, {"date": "Jun 2024", "val": 8.6}, {"date": "Mar 2025", "val": 11.0}]}
get_previous_notes
{"case_id": "PT-pseudo_4bfd4ec864d8", "previous_notes": [{"date": "13 Mar 2023", "author": "Dr. H. Martens (GP)", "text": "Clinical review on 13 March 2023 addressed a PSA increase to 6.3 ng/mL. Subsequent multiparametric MRI and systematic core biopsy yielded negative results for malignancy, with the encounter logged for ongoing urological monitoring."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and retrieving it now would not directly address the specific questions about the imaging, PSA trajectory, or prior management context.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the right mid-peripheral zone.
- psa_trend: PSA velocity of 1.56 ng/mL/yr (calculated from trend data).
- previous_notes: Prior biopsy was negative, and the patient is on ongoing urological monitoring.
AGAINST sampling this patient now:
- previous_notes: Prior biopsy was negative.
WHERE THIS LEANS
The evidence strongly supports the guideline criterion for re-biopsy due to the PI-RADS 5 finding, which aligns with the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 finding, PSA trend, and prior negative biopsy status) directly supports the EXPERT-PROTOCOL criterion for re-biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is clear as the prior, guideline criterion, and retrieved evidence all converged on this recommendation. The PI-RADS 5 finding on the mpMRI was decisive, aligning with the guideline criterion for re-biopsy when such a lesion is identified. This finding was supported by the PSA trend data and the context of the prior negative biopsy, which made the re-biopsy necessary.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
